March 2019

March 2019

In this month’s issue we delve into the controversy surrounding commercially available liquid biopsy tests. Despite the great potential of liquid biopsy, a recent study found high levels of incongruence between two tests that claim to guide treatment decisions for prostate cancer patients by analyzing ctDNA in the blood. We speak to four experts to investigate how issues with accuracy and consistency can be overcome and learn where the field is headed in the future. Also in this issue, read about the diagnostic potential of saliva, the best pieces of career advice shared by pathologists and laboratory professionals, and an interview with Dame Sue Hill, Chief Scientific Officer for England, and Senior Responsible Officer for Genomics in the National Health Service, London, UK.

Recent Issues